Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 4

Get the latest international news and world events from around the world.

Log in for authorized contributors

CISA exposes malware kits deployed in Ivanti EPMM attacks

The U.S. Cybersecurity and Infrastructure Security Agency (CISA) has published an analysis of the malware deployed in attacks exploiting vulnerabilities affecting Ivanti Endpoint Manager Mobile (EPMM).

The flaws are an authentication bypass in EPMM’s API component (CVE-2025–4427) and a code injection vulnerability (CVE-2025–4428) that allows execution of arbitrary code.

The two vulnerabilities affect the following Ivanti EPMM development branches and their earlier releases: 11.12.0.4, 12.3.0.1, 12.4.0.1, and 12.5.0.0.

Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities

T cells can be reprogrammed with transgenic antigen recognition receptors, including chimeric antigen receptors and T cell receptors, to selectively recognize and kill cancer cells. Such adoptive T cell therapies are effective in patients with certain haematological cancers but challenges persist, including primary and secondary resistance, a lack of efficacy in patients with solid tumours, a narrow range of targetable antigens, and time-consuming and complex manufacturing processes. CRISPR-based genome editing is a potent strategy to enhance cellular immunotherapies. Conventional CRISPR–Cas9 systems are useful for gene editing, transgene knock-in or gene knockout but can result in undesired editing outcomes, including translocations and chromosomal truncations. Base editing and prime editing technologies constitute a new generation of CRISPR platforms and enable highly precise and programmable installation of defined nucleotide variants in primary T cells. Owing to their high precision and versatility, base editing and prime editing systems, hereafter collectively referred to as CRISPR 2.0, are advancing to become the new standard for precision-engineering of cellular immunotherapies. CRISPR 2.0 can be used to augment immune cell function, broaden the spectrum of targetable antigens and facilitate streamlined production of T cell therapies. Notably, CRISPR 2.0 is reaching clinical maturity, with multiple clinical trials of CRISPR 2.0-modified cellular therapies currently ongoing. In this Review, we discuss emerging CRISPR 2.0 technologies and their progress towards clinical translation, highlighting challenges and opportunities, and describe strategies for the use of CRISPR 2.0 to advance cellular immunotherapy for haematological malignancies and solid tumours in the future.

#CRISPR9

Several persistent challenges limit the efficacy and applicability of adoptive T cell therapies for cancer, including suboptimal function and/or persistence in vivo, a narrow range of targetable antigens and complex manufacturing processes. This Review discusses the potential of ‘CRISPR 2.0’ precision gene-editing platforms, such as base editing and prime editing to address all of these challenges, and describes the progress made towards clinical translation of these technologies.

Measuring the quantum W state

Kyoto, Japan — The concept of quantum entanglement is emblematic of the gap between classical and quantum physics. Referring to a situation in which it is impossible to describe the physics of each photon separately, this key characteristic of quantum mechanics defies the classical expectation that each particle should have a reality of its own, which gravely concerned Einstein. Understanding the potential of this concept is essential for the realization of powerful new quantum technologies.

Meet the 2025 Ig Nobel Prize winners

Does alcohol enhance one’s foreign language fluency? Do West African lizards have a preferred pizza topping? And can painting cows with zebra stripes help repel biting flies? These and other unusual research questions were honored tonight in a virtual ceremony to announce the 2025 recipients of the annual Ig Nobel Prizes. Yes, it’s that time of year again, when the serious and the silly converge—for science.

Established in 1991, the Ig Nobels are a good-natured parody of the Nobel Prizes; they honor “achievements that first make people laugh and then make them think.” The unapologetically campy awards ceremony features miniature operas, scientific demos, and the 24/7 lectures whereby experts must explain their work twice: once in 24 seconds and the second in just seven words.

Acceptance speeches are limited to 60 seconds. And as the motto implies, the research being honored might seem ridiculous at first glance, but that doesn’t mean it’s devoid of scientific merit. In the weeks following the ceremony, the winners will also give free public talks, which will be posted on the Improbable Research website.

This deadly brain disorder can develop a decade after you get the measles — and it just killed a child

A school-aged child in L.A. recently died after developing a rare neurological disease years after contracting the measles.

Authorities didn’t reveal many details about the case, except that the child was infected with measles as an infant, before they were eligible for the vaccine.

Measles is a respiratory disease that spreads easily from person to person. The first dose of the measles, mumps and rubella (MMR) vaccine is routinely recommended for kids between 12 and 15 months old. A second dose is given before kindergarten or first grade.

Boron replaces metal by forming complexes with olefins, reducing toxicity and cost

When it comes to eliminating toxic and expensive heavy metals in the chemical industry, a new study from the University of Würzburg points the way forward.

The team led by chemistry professor Holger Braunschweig at the University of Würzburg is investigating the “metal-mimetic” properties of main group elements such as boron. They have shown that under certain conditions, boron can mimic the reaction behavior of metals without being toxic or as expensive as metals.

The article published in Nature Chemistry shows that boron can also form so-called π complexes with , which are similar in their properties and behavior to the complexes of transition metals with olefins. The latter compounds are intermediates in many large-scale catalytic processes in industry.

/* */